The Scientific Evidence of Regain Clinical trials back the prevalence of weight regain after stopping semaglutide: In the STEP-1 trial extension, participants who stopped semaglutide regained two-thirds of lost weight on average
MASLD affects 1 in 5 people in the UK but there are no medicines licensed to specifically treat the disease
In order to qualify for the study patients had to be at least 18 years of age with a diagnosis of type 2 diabetes and treated for at least three months with diet and exercise and/or a stable regiment of metformin, as well as an HbA1c level of 7-10% and a body weight of 60-110 kg
Ozempic Summary of Product Characteristics
Humans The most serious concern often raised is whether semaglutide increases the risk of thyroid cancer
Patients with a history of certain conditions , including pancreatitis, severe kidney disease, gastroparesis, or type 1 diabetes, should discuss risks carefully with their provider before starting treatment